The results of the ESCUDDO study, conducted by the Costa Rican Agency for Biomedical Research of the Inciensa Foundation (ACIB-FUNIN), in collaboration with the National Cancer Institute of the United States, were published on December 3 in the prestigious scientific journal The New England Journal of Medicine (NEJM), considered the most important worldwide, due to its high level of scientific influence.
The Costa Rican Biomedical Research Agency of the INCIENSA Foundation published the results of the ESCUDDO study in The New England Journal of Medicine, which investigates the effectiveness of a single dose of the human papillomavirus vaccine.
One dose of a bivalent or novalent human papillomavirus (HPV) vaccine was protective against HPV16 and HPV18 infections, and showed non-inferiority to two doses, according to the ESCUDDO randomized trial.
So far in 2025, the Ministry of Health reports 464 cases of the Human Papillomavirus, almost 50% more than last year. Women account for more than 90% of diagnoses, especially between 20 and 64 years of age.
Stomach cancer or gastric cancer has historically been one of the most common and deadly in Costa Rica. It is the third most common tumor and the deadliest cancer for men and the second deadliest for women, according to data from the National Tumor Registry and the National Institute of Statistics and Censuses (INEC).
The initial results of the ESCUDDO study, conducted in Costa Rica by the Costa Rican Agency for Biomedical Research (ACIB-FUNIN) in collaboration with the National Cancer Institute of the United States, confirm that a single dose of the Human Papillomavirus (HPV) vaccine offers the same protection as two doses.
Link of the news:
Summary of the news: These are the first results of ESCUDDO, a study launched in the country in 2017 to demonstrate the effectiveness of a single dose of the human papillomavirus vaccine.
Link of the news:
https://drive.google.com/file/d/18DOCVSw9nKbqBsFMZqpGFmUXkp2BR7Be/view?usp=sharing
A study conducted in Costa Rica with 19,460 women between the ages of 12 and 16 could transform decisions about human papillomavirus (HPV) vaccination made around the world.
Women who received a single dose of the human papillomavirus (HPV) vaccine in Costa Rica 16 years ago maintain antibodies against the virus and have not developed infections with the types of viruses covered by the injection. These are the most recent conclusions of a study that began in 2004 with the clinical trial that led to testing the vaccine in women between 18 and 25 years old.
Link of the news:
https://www.nacion.com/el-pais/una-sola-dosis-de-vacuna-contra-papiloma-mantiene/6YKOZHUCXFFR7GS45J2LXCYVUA/story/
Gabriel Sancho Zúñiga and Keilyn Alfaro López are 23 years old and both have been diagnosed with cancer. At 22, he developed a tumor in the mediastinum, an area of the thorax that separates the two lungs; she was diagnosed with a brain tumor at 21.
Link of the news:
